Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 130

1.

Oral ghrelin receptor agonist MK-0677 increases serum insulin-like growth factor 1 in hemodialysis patients: a randomized blinded study.

Campbell GA, Patrie JT, Gaylinn BD, Thorner MO, Bolton WK.

Nephrol Dial Transplant. 2018 Mar 1;33(3):523-530. doi: 10.1093/ndt/gfw474.

2.

Dependence of Glomerulonephritis Induction on Novel Intraglomerular Alternatively Activated Bone Marrow-Derived Macrophages and Mac-1 and PD-L1 in Lupus-Prone NZM2328 Mice.

Sung SJ, Ge Y, Dai C, Wang H, Fu SM, Sharma R, Hahn YS, Yu J, Le TH, Okusa MD, Bolton WK, Lawler JR.

J Immunol. 2017 Apr 1;198(7):2589-2601. doi: 10.4049/jimmunol.1601565. Epub 2017 Feb 20.

3.

Growth hormone levels in ESRD patients.

Campbell GA, Bolton WK.

Semin Dial. 2014 Nov-Dec;27(6):555-8. doi: 10.1111/sdi.12278. Epub 2014 Jul 3. No abstract available.

PMID:
24995514
4.

Balancing cancer risk and efficacy of using cyclophosphamide to treat idiopathic membranous nephropathy.

Khan S, Bolton WK.

Clin J Am Soc Nephrol. 2014 Jun 6;9(6):1001-4. doi: 10.2215/CJN.04130414. Epub 2014 May 22. No abstract available.

5.

A good reason to measure 24-hour urine creatinine excretion, but not to assess kidney function.

Kalantari K, Bolton WK.

Clin J Am Soc Nephrol. 2013 Nov;8(11):1847-9. doi: 10.2215/CJN.09770913. Epub 2013 Oct 24. No abstract available.

6.

Association of plasma des-acyl ghrelin levels with CKD.

Gupta RK, Kuppusamy T, Patrie JT, Gaylinn B, Liu J, Thorner MO, Bolton WK.

Clin J Am Soc Nephrol. 2013 Jul;8(7):1098-105. doi: 10.2215/CJN.09170912. Epub 2013 Jun 6.

7.

Comanagement of diabetic kidney disease by the primary care provider and nephrologist.

Bowman BT, Kleiner A, Bolton WK.

Med Clin North Am. 2013 Jan;97(1):157-73. doi: 10.1016/j.mcna.2012.10.012. Review.

PMID:
23290736
8.

Activated CD4+ T cells target mesangial antigens and initiate glomerulonephritis.

Scindia Y, Nackiewicz D, Dey P, Szymula A, Bajwa A, Rosin DL, Bolton WK, Okusa MD, Deshmukh U, Bagavant H.

Nephron Exp Nephrol. 2012;121(1-2):e1-9. doi: 10.1159/000342368. Epub 2012 Oct 19.

9.

Factors affecting response and tolerability to ferumoxytol in nondialysis chronic kidney disease patients.

Fishbane S, Bolton WK, Winkelmayer WC, Strauss W, Li Z, Pereira BJ.

Clin Nephrol. 2012 Sep;78(3):181-8.

PMID:
22874106
10.

The normal HCT trial re-revisited: what were the actual findings?

Besarab A, Bolton WK, Nissenson AR, Schwab SJ.

Kidney Int. 2012 Jul;82(2):242; author reply 242-3. doi: 10.1038/ki.2012.204. No abstract available.

11.

Referral and comanagement of the patient with CKD.

Campbell GA, Bolton WK.

Adv Chronic Kidney Dis. 2011 Nov;18(6):420-7. doi: 10.1053/j.ackd.2011.10.006. Review.

PMID:
22098660
12.

Monocyte/macrophage chemokine receptor CCR2 mediates diabetic renal injury.

Awad AS, Kinsey GR, Khutsishvili K, Gao T, Bolton WK, Okusa MD.

Am J Physiol Renal Physiol. 2011 Dec;301(6):F1358-66. doi: 10.1152/ajprenal.00332.2011. Epub 2011 Aug 31.

13.

Vascular access for HD: aligning payment with quality.

Amedia CA Jr, Bolton WK, Cordray T, Hakim R, Howard R, Jackson J, Kulawik D, Lyon M, Mahoney D, Messana A, Nissenson A, Oviatt L, Parlato D, Roddy S, Solid C.

Semin Dial. 2011 Jan-Feb;24(1):37-40. doi: 10.1111/j.1525-139X.2010.00816.x.

PMID:
21338392
14.

Chronic sphingosine 1-phosphate 1 receptor activation attenuates early-stage diabetic nephropathy independent of lymphocytes.

Awad AS, Rouse MD, Khutsishvili K, Huang L, Bolton WK, Lynch KR, Okusa MD.

Kidney Int. 2011 May;79(10):1090-8. doi: 10.1038/ki.2010.544. Epub 2011 Feb 2.

15.

Editorial: Are men rats? Dendritic cells in autoimmune glomerulonephritis.

Sung SS, Bolton WK.

J Leukoc Biol. 2010 Nov;88(5):831-5. doi: 10.1189/jlb.0610356. No abstract available.

PMID:
21041514
16.

Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria.

Adler SG, Schwartz S, Williams ME, Arauz-Pacheco C, Bolton WK, Lee T, Li D, Neff TB, Urquilla PR, Sewell KL.

Clin J Am Soc Nephrol. 2010 Aug;5(8):1420-8. doi: 10.2215/CJN.09321209. Epub 2010 Jun 3.

17.

Pulmonary renal syndrome and emergency therapy.

Bolton WK.

Contrib Nephrol. 2010;165:166-173. doi: 10.1159/000313756. Epub 2010 Apr 20.

PMID:
20427967
18.

Nephrogenic systemic fibrosis: a survey of nephrologists' perceptions and practices.

Abdel-Kader K, Patel PR, Kallen AJ, Sinkowitz-Cochran RL, Bolton WK, Unruh ML.

Clin J Am Soc Nephrol. 2010 Jun;5(6):964-71. doi: 10.2215/CJN.00140110. Epub 2010 Mar 18.

19.

Potential new therapeutic agents for diabetic kidney disease.

Turgut F, Bolton WK.

Am J Kidney Dis. 2010 May;55(5):928-40. doi: 10.1053/j.ajkd.2009.11.021. Review.

PMID:
20138415
20.

Ferumoxytol for the treatment of anemia in chronic kidney disease.

Rosner MH, Bolton WK.

Drugs Today (Barc). 2009 Nov;45(11):779-86. doi: 10.1358/dot.2009.45.11.1420459. Review.

PMID:
20126670

Supplemental Content

Loading ...
Support Center